Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 16/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 11/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | TSPO | P30536 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | PTGFR | P43088 | 1/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.52 |
| ▸ | PTGIR | P43119 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | PDE2A | O00408 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255659 | 0.94 | PDE2A (0.55) | PTGDRTBXA2RPTGER1PTGFRPTGER3 | |
| SCHEMBL1254584 | 0.94 | PDE2A (0.55) | PTGDRTBXA2RPTGER1PTGFRPTGER3 | |
| SCHEMBL13407090 | 0.86 | PTGDR (0.39) | PTGDRTBXA2RPDE4ATSPOPTGER1 | |
| SCHEMBL14562369 | 0.86 | PTGDR (0.39) | PTGDRTBXA2RPDE4ATSPOPTGER1 | |
| SCHEMBL11918206 | 0.82 | PDE2A (0.44) | PTGDRTBXA2RPTGER1PTGFRPTGER3 | |
| SCHEMBL5522526 | 0.82 | PTGDR (0.38) | PTGDRTBXA2RPDE4ATSPOPTGER1 | |
| SCHEMBL5420470 | 0.81 | PTGDR (0.48) | PTGDRTBXA2RPDE4ATSPOPTGER1 | |
| SCHEMBL4093843 | 0.81 | PTGDR (0.48) | PTGDRTBXA2RPDE4ATSPOPTGER1 | |
| SCHEMBL1255227 | 0.81 | PDE2A (0.43) | PTGDRTBXA2RPTGER1PTGFRPTGER3 | |
| SCHEMBL6820539 | 0.78 | TBXA2R (0.53) | PTGDRTBXA2RPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | MERCK FROSST CANADA & CO. (CA) | 2007-03-08 | — | — | US | disclosed |
| EP-1631547-A1 | FLUORO-METHANESULFONYL-SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004103970-A1 | FLUORO-METHANESULFONYL-SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | PTGDR2, PTGER2, PTGDR | PTGDR 3/4885TBXA2R 18/4885PDE4A 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.